Research and development facility
The Biomedical Engineering and Advanced Manufacturing (BEAM) centre is located in McMaster Innovation Park in Hamilton, Ontario, Canada.
Also known as the Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing, the C$33m ($25m) facility was jointly developed by McMaster University and the Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI) under a partnership formed in January 2015.
The joint project was inaugurated in March 2018. It aims to develop technologies for eye care, point-of-care medical devices and cancer treatments.
The project created 74 jobs and will support 35 business-academic collaborations for developing new products, ideas and clinical trials.
Located close to Hamilton town, the BEAM centre is easily accessible from Highway 403, the McMaster University and the McMaster Innovation Park. It is also near Toronto Pearson International Airport and John C. Munro Hamilton International Airport.
Ontario was chosen to locate the new facility due to the low business costs and well-educated talent pool. In addition, the region has an emerging life sciences industry with more than 1,600 companies.
The facility covers a 20,000ft² area, which includes 16,000ft² laboratory spaces that facilitate mammalian and bacterial cell culture, synthesis of biomaterials and bio-analysis.
The facility also has 4,000ft² of mixed-use office space, which includes meeting rooms. An atrium area is also available, which is designed to enable researchers to meet and collaborate.
A 50,000ft² area is being developed next to the facility to house incubator space to support commercialisation activities for BEAM.
The BEAM centre focuses on diagnostics, biomarkers, cell therapies and biomaterials.
The diagnostics unit focuses on printable next-generation diagnostic tests, which can be applied to point-of-care (POC) settings. Some of the core areas within the unit include optimisation of sensor surfaces, printable components development for POC sensors, generating application-specific DNA-based sensors, and integration and scale-up of ISO-compliant POC sensors.
The biomarker unit collaborates with the RIBOLUTION Biomarker Centre at the Fraunhofer IZI in Leipzig, identifying novel biomarkers on the basis of ribonucleic acids (RNA). The unit identifies biomarkers using genomic analysis methods and next-generation sequencing to develop new diagnostic tests. Prostate cancer, chronic obstructive pulmonary disease and infectious diseases are the areas of focus of the unit.
The cell therapy unit carries out research and development (R&D) activities on novel targeted therapies applied for different cancer indications. The novel therapies are developed using chimeric antigen receptor transduced autologous immune cells. The unit also offers a systematic approach to the manual production of the autologous cell therapies.
The biomaterials unit at BEAM develops biomaterial for ocular applications such as new drug delivery platforms, better contact lens materials and new intraocular lens materials.
The project received a C$12m ($9.1m) federal grant, which was provided by Hamilton and the provincial governments.
Diamond Schmitt Architects is the architect for the research facility.
The BEAM centre will help accelerate product pipelines of its corporate partners and provide operational expertise to characterise test components and optimise assays.
The McMaster and Fraunhofer project management base experience will be helpful to meet deadlines for various projects and achieve the set targets. The centre will have access to advanced instrumentation systems from both McMaster and Fraunhofer. Some of the equipment include biological preparation equipment, equipment for high-throughput screening, bio-selectivity, and surface characterisation.
The BEAM centre will also have access to the existing intellectual property of the two institutes.
Seqirus, an influenza vaccine maker, is building a new cell-based influenza vaccine manufacturing facility in Melbourne, Australia. The facility will…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Thermo Fisher Scientific opened a new manufacturing facility in Lenexa, Kansas to meet the increasing demand for viral transport media…